Anzeige
Meldung des Tages: Milliardenmarkt, eigene KI-Plattform, starke Kasse: Ist diese Aktie massiv unterbewertet?

Neurosense Therapeutics News

Aktie
WKN:  A3DFK1 ISIN:  IL0011809592 US-Symbol:  NRSN Branche:  Biotechnologie Land:  Israel
0,71 €
+0,02 €
+2,90%
08:09:28 Uhr
Depot/Watchlist
Marktkapitalisierung *
16,72 Mio. €
Streubesitz
72,74%
KGV
-2,73
Index-Zuordnung
-

Neurosense Therapeutics News

18.02.26 - PR Newswire
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS PR Newswire
09.02.26 - PR Newswire
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition PR Newswire
21.01.26 - PR Newswire
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease PR Newswire
08.01.26 - PR Newswire
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
World-​Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB PR Newswire
22.12.25 - PR Newswire
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study PR Newswire
04.12.25 - PR Newswire
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 PR Newswire
24.11.25 - PR Newswire
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS PR Newswire
03.11.25 - PR Newswire
NeuroSense to Host Investor Webinar on December 8, 2025
NeuroSense to Host Investor Webinar on December 8, 2025 PR Newswire
06.10.25 - PR Newswire
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers PR Newswire
10.09.25 - PR Newswire
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-​Derived Neurons PR Newswire
04.09.25 - PR Newswire
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price PR Newswire
01.08.25 - PR Newswire
NeuroSense Provides Business Update and Progress for the First Half of 2025
NeuroSense Provides Business Update and Progress for the First Half of 2025 PR Newswire
22.07.25 - PR Newswire
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
Award-​Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization ...
07.05.25 - PR Newswire
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch PR Newswire
24.04.25 - PR Newswire
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update PR Newswire
09.04.25 - PR Newswire
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-​Modifying ALS Treatment PR Newswire
04.04.25 - PR Newswire
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting PR Newswire

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »